Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:BLUENASDAQ:GLUENASDAQ:VIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.27+5.4%$1.03$0.86▼$3.60$76.63M0.05288,542 shs242,763 shsBLUEbluebird bio$4.97$4.53$3.20▼$28.60$48.67M0.27435,475 shsN/AGLUEMonte Rosa Therapeutics$4.91-2.0%$4.35$3.21▼$12.40$298.57M1.41.07 million shs143,059 shsVIGLVigil Neuroscience$7.88-0.1%$3.40$1.31▼$7.95$367.54M3.43675,582 shs1.98 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+17.65%+22.44%0.00%-54.20%BLUEbluebird bio0.00%0.00%+42.41%+26.14%-72.54%GLUEMonte Rosa Therapeutics0.00%+21.01%+21.90%-16.92%+25.88%VIGLVigil Neuroscience0.00%0.00%+225.62%+228.33%+71.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.7589 of 5 stars3.72.00.00.03.51.70.6BLUEbluebird bio2.6733 of 5 stars3.15.00.00.00.61.71.3GLUEMonte Rosa Therapeutics2.3061 of 5 stars3.40.00.00.03.23.30.6VIGLVigil Neuroscience3.3825 of 5 stars4.03.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33479.71% UpsideBLUEbluebird bio 2.25Hold$44.60797.38% UpsideGLUEMonte Rosa Therapeutics 2.75Moderate Buy$15.50215.68% UpsideVIGLVigil Neuroscience 2.00Hold$10.8037.14% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, VIGL, ABOS, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/22/2025VIGLVigil NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ABLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14GLUEMonte Rosa Therapeutics$159.49M1.89N/AN/A$3.58 per share1.37VIGLVigil NeuroscienceN/AN/AN/AN/A$3.24 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%8/12/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)GLUEMonte Rosa Therapeutics-$135.35M$0.08N/AN/AN/AN/A-62.68%-38.83%8/14/2025 (Estimated)VIGLVigil Neuroscience-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)Latest BLUE, VIGL, ABOS, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 million5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/20/2025Q4 2024GLUEMonte Rosa Therapeutics-$0.37$0.23+$0.60$0.23$43.73 million$14.00 million3/13/2025Q4 2024VIGLVigil Neuroscience-$0.49-$0.57-$0.08-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43BLUEbluebird bio0.370.510.33GLUEMonte Rosa TherapeuticsN/A6.036.03VIGLVigil NeuroscienceN/A3.723.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%BLUEbluebird bio87.43%GLUEMonte Rosa Therapeutics79.96%VIGLVigil Neuroscience83.64%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%BLUEbluebird bio1.40%GLUEMonte Rosa Therapeutics6.90%VIGLVigil Neuroscience18.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.44 millionOptionableVIGLVigil Neuroscience4046.67 million27.38 millionNot OptionableBLUE, VIGL, ABOS, and GLUE HeadlinesRecent News About These CompaniesWall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a BetJune 9 at 11:01 AM | zacks.comSquarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9 at 3:23 AM | marketbeat.comMillennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9 at 3:09 AM | marketbeat.comJane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9 at 3:07 AM | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LPJune 8 at 3:39 AM | marketbeat.comVigil Neuroscience halts Phase 2 trial for ALSP treatmentJune 5, 2025 | investing.comVigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II TrialJune 5, 2025 | biospace.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...June 5, 2025 | morningstar.comDisappointing results see Vigil Neuro drop iluzanebart developmentJune 4, 2025 | thepharmaletter.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the FirmJune 4, 2025 | prnewswire.comVigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSPJune 4, 2025 | globenewswire.comShould You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?June 2, 2025 | zacks.comHC Wainwright Cuts Earnings Estimates for Vigil NeuroscienceMay 31, 2025 | americanbankingnews.comHC Wainwright Has Bearish Forecast for VIGL FY2026 EarningsMay 30, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Stifel NicolausMay 30, 2025 | americanbankingnews.comStifel cuts Vigil Neuroscience stock rating, lowers target to $8May 29, 2025 | investing.comVigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to HoldMay 29, 2025 | marketbeat.comStifel Downgrades Vigil Neuroscience (VIGL)May 29, 2025 | msn.comHC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)May 28, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)May 28, 2025 | msn.comWoodline Partners LP Has $831,000 Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Top Dividend Stocks Analysts Are Bullish on Right NowBy Chris Markoch | June 6, 2025View 3 Top Dividend Stocks Analysts Are Bullish on Right Now3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBLUE, VIGL, ABOS, and GLUE Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.26 +0.07 (+5.42%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Monte Rosa Therapeutics NASDAQ:GLUE$4.91 -0.10 (-2.00%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Vigil Neuroscience NASDAQ:VIGL$7.88 -0.01 (-0.06%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
